Control Bionics Ltd. (AU:CBL)
ASX:CBL
CBL Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.09
Previous CloseN/A
Volume65.91K
Average Volume (3M)173.99K
Market Cap
AU$24.72M
Enterprise ValueAU$16.37M
Total Cash (Recent Filing)AU$3.06M
Total Debt (Recent Filing)AU$258.10K
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding411,961,880
10 Day Avg. Volume327,267
30 Day Avg. Volume173,987
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.44
Price to Sales (P/S)1.29
P/FCF Ratio-1.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA recurring top-line expansion of ~16% indicates durable demand and product adoption in its core assistive-tech niche. Sustained revenue growth, if maintained, supports scale benefits and the potential to leverage fixed-cost base to improve margins over the next several quarters.
Conservative Balance SheetA low leverage profile and strong equity ratio reduce refinancing and solvency risk, giving the company flexibility to fund operations or raise capital without immediate distress. This financial conservatism supports continuity while management works toward profitability.
Specialized Assistive-Technology FocusA focused product set (wearables plus software for AAC and hands-free control) serves mission-critical users with severe disabilities. That specialization creates durable customer stickiness and higher switching costs, supporting steady recurring demand and differentiated market positioning.
Bears Say
Negative Operating Cash FlowOperating cash flow is negative and free cash flow has declined, signaling the business is not converting revenue into cash. This structural cash-generation shortfall increases reliance on external funding, constrains reinvestment capacity, and raises execution risk over coming quarters.
Weak ProfitabilityDespite healthy gross margins, persistent negative EBIT and net margins show operating costs or overhead outpacing revenue. Structural unprofitability limits the firm's ability to self-fund growth, delays margin improvement, and makes long-term sustainability contingent on cost control or scale.
Negative Return On EquityA negative ROE indicates capital deployed is eroding shareholder value rather than compounding it. Coupled with losses and weak cash flow, this raises the likelihood of future equity raises or dilution and constrains access to patient capital needed for sustained product development.
Control Bionics Ltd. News
CBL FAQ
What was Control Bionics Ltd.’s price range in the past 12 months?
Control Bionics Ltd. lowest share price was AU$0.03 and its highest was AU$0.09 in the past 12 months.
What is Control Bionics Ltd.’s market cap?
Control Bionics Ltd.’s market cap is AU$24.72M.
When is Control Bionics Ltd.’s upcoming earnings report date?
Control Bionics Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 143 days.
How were Control Bionics Ltd.’s earnings last quarter?
Control Bionics Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Control Bionics Ltd. overvalued?
According to Wall Street analysts Control Bionics Ltd.’s price is currently Overvalued.
Does Control Bionics Ltd. pay dividends?
Control Bionics Ltd. does not currently pay dividends.
What is Control Bionics Ltd.’s EPS estimate?
Control Bionics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Control Bionics Ltd. have?
Control Bionics Ltd. has 411,961,880 shares outstanding.
What happened to Control Bionics Ltd.’s price movement after its last earnings report?
Control Bionics Ltd. reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Control Bionics Ltd.?
Currently, no hedge funds are holding shares in AU:CBL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Control Bionics Ltd. Stock Smart Score
Company Description
Control Bionics Ltd.
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America. The company offers NeuroNode Trilogy and NeuroNode3 systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a device to control a range of devices, including wheelchairs, dining robots, and gaming systems; Uno Touch, a speech generating device; and other sensors for multiple applications. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is based in Camberwell, Australia.
Technical Analysis
Options Prices
Currently, No data available
---